Table 2.

Interleukin 33 and skin. Results are inclusive of both psoriasis and atopic dermatitis. The results are ordered by year and a quick recap was produced by author’s name, disease, specimens and results.

Author	Disease Studied	Species Examined	Year	Results
Raimondo et al. [18]	Pso	Humans	2017	IL-33 from psoriatic plaques induces the release of pro-osteoclatogenic factors
Meephansan et al. [19]	Pso	Humans	2018	Decrease of IL-33 levels after treatment with MTX, increase after NB-UVBtreatment
Borsky et al. [20]	Pso	Humans	2020	High sera levels in psoriatic patients, no correlation with the severity of clinical presentation
Chen et al. [21]	Pso	Humans	2020	High sera and intraepidermal levels of IL-33 in patients with moderate-severe psoriasis
Salamon et al. [22]	AD	Colture cells, animals	2017	IL-33 induces a production of IL-2
Jang et al. [23]	AD	Colture cells	2017	HDM induces the release of IL-33 and IL-25
Nygaard et al. [24]	AD	Colture cells	2017	Down regulation of members of the epidermal differentiation complex after exposure to IL-33
Tang et al. [25]	AD	Animals	2018	Knock down of SHAPIN causes AD via IL-33
Peng et al. [26]	AD	Animals	2018	Antibodies anti-IL33 lead to reduction of lichenification, redness and scaling
Ryu et al. [27]	AD	Colture cells	2018	Low levels of claudin-1 after exposure to high levels of IL-33
Sawada et al. [28]	AD	Animals	2019	Increased levels of IL-33 in the model of disease
Chen et al. [29]	AD	Humans	2019	Etokimab: Good tolerability and efficacy (EASI score)
Nakamura et al. [30]	AD	Humans	2019	Correlation with levels of IL-33 and degree of lichenification and pruritus
Seo et al. [31]	AD	Humans	2020	High TRPV3 levels in AD TRPV3 induces the production of IL-33
Dai et al. [32]	AD	Colture cells	2020	Dermatophagoides pteronissynus allergens induce overexpression of IL-33
Pietka et al. [33]	AD	Animals	2020	Wild type and knockout mice for IL-33 and its receptor develop AD lesions after treatment with calcipotriol